Evome Medical Technologies INC
Market Movers (8-K)
OTC.Pink
8-K: Evome Medical Technologies Strengthens Creditor Ties, Cancels Debt Extension LOI After Simbex Sale
Evome Medical Technologies has strengthened its relationship with its senior lender, Pathward, after selling its Simbex unit and canceling a related debt extension agreement.
OTC.Pink
8-K: Evome Medical Technologies Sells Simbex R&D Unit to Riddell for $3.55M, Strengthening Balance Sheet
Evome Medical Technologies Inc. has sold its Simbex R&D business unit to EB Sports Corp., the parent company of Riddell Sports Group, for $3.55 million, aiming to reduce debt and focus on its Biodex product line.
OTC.Pink
Evome Medical Technologies reports a successful turnaround, achieving positive adjusted EBITDA for fiscal year 2023, driven by a strong fourth quarter performance.
Better than expected
OTC.Pink
8-K: Evome Medical Technologies Appoints Seasoned Healthcare Executives to Board, Names New Chairman
Evome Medical Technologies has appointed Wayne Anderson and Bill Garbarini to its Board of Directors and named Kenneth Kashkin as Chairman, marking a significant step in the company's transformation.
OTC.Pink
Evome Medical Technologies has extended its Simbex acquisition debt to June 2025, increased sales targets by 7.5%, and raised Biodex product prices by 2% for 2024.
OTC.Pink
Evome Medical Technologies has reduced its acquisition debt and strengthened its management team as it prepares to launch new medical devices in 2024.
Better than expected
Annual Reports (10-K)
OTC.Pink
10-K: Evome Medical Technologies Reports Fiscal Year 2023 Results Amidst Strategic Shifts and Divestitures
Evome Medical Technologies reports its fiscal year 2023 results, highlighting revenue growth driven by acquisitions, while also detailing strategic divestitures and ongoing financial challenges.
Capital raise
Worse than expected